Zydus Lifesciences gets USFDA nod to market generic drugs
Zydus Lifesciences gets USFDA nod to market generic drugs is drawing significant interest across the industry.
NEW DELHI, Feb 28: Zydus Lifesciences on Saturday said it has received approval from the US health regulator to market generic anti-parasitic and leprosy medications. The company has received final approvals from the US Food and Drug Administration (USFDA) for Ivermectin Tablets (3 mg) and Dapsone Tablets ( 25 mg and 100 mg), the Ahmedabad-based drug said in a statement. Ivermectin tablets are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans, specifically intestinal strongyloidiasis and onchocerciasis. […]
Experts suggest this could influence future trends and innovation in the sector.
More updates are expected as the story develops.
Related Articles
- RACL Geartech soars 14%, hits 52-wk high; what's driving auto parts stock?
- Beer Market to Reach $873.0 Billion, Globally, by 2034 at 2.7% CAGR: Allied Market Research
- Earnings revival set to lift Indian markets in FY27: Manish Gunwani
- FII Flows: Not Korea, not India, but foreign investors are making a beeline for these markets
Source: Original →